New drug regimen for multidrug-resistant tuberculosis shows early effectiveness in 85 percent of patients in a cohort including many with serious comorbidities. The results suggest a global need for expanded access to two recently developed medicines, bedaquiline and delamanid. Study cohort included many people who would have been excluded from trials because of comorbidities, severity of disease or extent of drug resistance. Findings highlight the importance of innovative regimens to improve outcomes for patients with multidrug-resistant tuberculosis.
- Satellite images confirm uneven impact of climate change
- Understanding traditional Chinese medicine can help protect species
- Scientists claim controversial results of comets observations are consistent
- The smell of cooperation
- Princeton scientists solve the mystery behind an enigmatic organelle, the pyrenoid